| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.0061 | 0.8 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.9 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.9 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | GW 441756 | GDSC1000 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.9 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.0083 | 0.9 |